Hot Features
Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition ... BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) is poised to potentially launch in the 2022-23 timeframe. Mehr anzeigen
BioMarin Presents Real-World Evidence Further Supporting Safety and Efficacy of VOXZOGO® (vosoritide) in Children with Achondroplasia at the European Society for Paediatric Endocrinology (ESPE...
BioMarin to Participate in Three Upcoming Investor Conferences PR Newswire SAN RAFAEL, Calif., Nov. 6, 2024 UBS Global Healthcare Conference on November 12 at 11:00 am PSTJefferies London...
BioMarin Announces 28% Y/Y Total Revenue Growth in the Third Quarter and Increase in Full-year 2024 Guidance; Reaffirms Long-term Guidance and Outlook PR Newswire SAN RAFAEL, Calif., Oct. 29...
WILMETTE, Ill., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biotechnology company focused on developing innovative treatments for patients with...
BioMarin to Host Third Quarter 2024 Financial Results Conference Call and Webcast on Tuesday, October 29, 2024, at 4:30pm ET PR Newswire SAN RAFAEL, Calif., Oct. 16, 2024 SAN RAFAEL, Calif., Oct...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.42 | -0.635593220339 | 66.08 | 67.85 | 63.93 | 1325977 | 65.74430695 | CS |
| 4 | 1.78 | 2.78647463995 | 63.88 | 67.87 | 62.84 | 1490673 | 65.69198138 | CS |
| 12 | -4.89 | -6.93125442948 | 70.55 | 71.235 | 61.15 | 1443877 | 66.95560891 | CS |
| 26 | -18.41 | -21.898417985 | 84.07 | 94.85 | 61.15 | 1853195 | 76.86209791 | CS |
| 52 | -30.73 | -31.8809005084 | 96.39 | 99.25 | 61.15 | 1787680 | 81.01888791 | CS |
| 156 | -19.89 | -23.2495616598 | 85.55 | 117.77 | 61.15 | 1480620 | 86.52041463 | CS |
| 260 | -19.79 | -23.1597425395 | 85.45 | 131.945 | 61.15 | 1471006 | 86.09789802 | CS |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
